News coverage about Celldex Therapeutics (NASDAQ:CLDX) has been trending positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 49.2863013604298 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Is Celldex Therapeutics Stock About to Skyrocket? (finance.yahoo.com)
- Why Celldex Therapeutics Stock Crashed in February (finance.yahoo.com)
- Global Hypopharyngeal Cancer Treatment Market 2018- Celldex Therapeutics Inc, Incyte Corp (openpr.com)
- Leerink Swann Equities Analysts Decrease Earnings Estimates for Celldex Therapeutics, Inc. (CLDX) (americanbankingnews.com)
- Brokers Offer Predictions for Celldex Therapeutics, Inc.’s Q1 2018 Earnings (CLDX) (americanbankingnews.com)
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up $0.04 during trading hours on Wednesday, hitting $2.62. 154,858 shares of the company were exchanged, compared to its average volume of 1,319,623. The company has a market capitalization of $397.83, a price-to-earnings ratio of -3.49 and a beta of 2.63. Celldex Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $3.75.
Several research analysts recently commented on the stock. BidaskClub upgraded shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a report on Thursday, March 8th. Leerink Swann restated a “market perform” rating and issued a $3.00 price target (down previously from $4.00) on shares of Celldex Therapeutics in a report on Thursday, March 8th. WBB Securities reiterated a “buy” rating and set a $10.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, March 7th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.38.
TRADEMARK VIOLATION NOTICE: This piece was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/14/favorable-media-coverage-somewhat-unlikely-to-impact-celldex-therapeutics-cldx-share-price/1923390.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.